GenomeDx improves cancer and urology patient care

Cambridge Oncometrix moves prostate cancer diagnostic forward

Avenda Health: treating prostate cancer in the clinic while preserving quality of life

Web tool aims to better inform and refine need for treatment in early prostate cancer

A new tool to predict an individual's prognosis following a prostate cancer (lat. Prostate Carcinoma) diagnosis that could help prevent unnecessary treatment and related side effects has been developed by the researchers at the University of Cambridge (UCamb). The tool, PREDICT Prostate brings together the latest evidence and mathematical models to give a personalised prognosis, which the researchers say will empower patients as they discuss treatment options with their consultant. When a patient is diagnosed with prostate cancer, they are currently classified as low, intermediate or high risk. Depending on the patient's risk group, clinicians will recommend either an 'active monitoring' approach or treatment. Treatment options include radiotherapy or surgery and can have potentially significant side-effects, including erectile dysfunction and urinary incontinence.

by
6 days ago

A liquid biopsy technology for prostate cancer

New technology for a 'liquid biopsy' to identify which patients might not respond to standard therapy for prostate cancer (lat. Prostate Carcinoma) before it is delivered has been developed by the researchers at the University of Toronto (UniToronto). Screening for drug resistance is key to improving treatment approaches for many cancers. It’s important for patients not to be on a therapy that won’t help them and it’s also important for health-care systems to avoid, whenever possible, delivering ineffective treatments. The ability to screen patients using a blood sample as opposed to more invasive techniques required for conventional biopsies is also a step forward.

by
7 days ago

Fusion: targeted prostate biopsies

Traditionally, men suspected of having prostate cancer are diagnosed through systematic biopsies that are performed under ultrasound imaging guidance. In this procedure, urologists take 12- 15 biopsy samples at random and hope they find cancer if it is present. Unfortunately, traditional biopsies can miss cancer in 25% of men who have it. Moreover, if cancer is detected, it is very challenging to determine its extent and severity to recommend the best treatment. However, Focal Healthcare, a Canadian-based medical device company, is committed to improving the lives of prostate cancer patients and their families through technical innovation. By developing imaging tools that emphasize accuracy, efficiency and accessibility, Focal Healthcare strives to advance prostate cancer diagnosis and management in clinics and hospitals of all sizes. The company designs and manufactures all its products at its headquarters in Toronto, Canada.

by
7 days ago

Pioneering AI-based cancer diagnostics in pathology

End-to-end solutions for prostate cancer diagnosis and treatment

Erythra: a simple solution to difficult problems

xRfiber improves people's lives using AI

xRapid Group is a MedTech company is based primarily in London, UK with offices in Marseille, France as well as in Jakarta, Indonesia and San Francisco, USA. The company's mission is improving people’s lives through AI applications. It creates mobile applications, which provide faster, more precise diagnoses of a number of serious diseases, including tuberculosis (lat. Phthisis) and malaria (lat. malariae). Therefore, xRapid Group, which was founded in 2015, provides a number of innovative applications such as xRapid that is a malaria test, xRblood, and xRfiber.

by
13 days ago

New approach for tuberculosis drugs

A novel approach for developing new tuberculosis (lAat. Phthisis) drugs has been suggested by the ETH team. New active substances that are able to kill multidrug-resistant strains of the disease are therefore urgently needed. Altmann and his team have now laid the foundation for new tuberculosis drugs, and they were inspired by a bacteria-derived antibiotic called pyridomycin. Pyridomycin inhibits the growth of the tuberculosis pathogen Mycobacterium tuberculosis, but it is degraded relatively quickly and is therefore ineffective. However, by using the structure of pyridomycin, the researchers have designed a molecule that has several advantages over the natural active substance.

by
13 days ago

FUSION GENOMICS: a new era in pathogen sequencing

FUSION GENOMICS is a Vancouver-based company that is advancing molecular diagnostics by developing identification tests for pathogens using proprietary technologies in combination with Next Generation Sequencing. Its ONETest™ products, in combination with the FUSIONCloud™ data analysis platform, enable rapid identification of the genetic signatures of human pathogens and cancers accurately and economically. Furthermore, FUSION’s ONETest™ platform is currently being tested at various key opinion leaders in Canada and the European Union.

by
13 days ago

Cookies help us deliver our Services. By using our website or clicking I agree, you agree to our use of cookies. Learn more about our cookie and privacy policy.

I AGREE

THE MOST ADVANCED SCIENCE SPINOFF SCOUTING SYSTEM:

100% Free of Cost For Scientists:

  • One hour of USA/EU attorney consulting
  • 24/7 support of 24 in-house professionals
  • 10 GB space for every scientist (own German Servers)
  • Syndicates with the leading professionals
  • 2,000 000 views of top spinoff are guaranteed
  • The largest DB of professional Investors - over 30.000

100% Free of Cost For Investors:

  • Investment information on 8,000+ spinoffs per year
  • All documents in one place (after NDA)
  • Testimonials from Key Opinion Leaders
  • AI-SDB hides irrelevant spinoffs - saved time up to 90% 
  • One-Click-Reports (OCRs) in own tailored design (PDF)

100% Free of Cost For Universities:

  • Professional Science Spinoff University Report (PDF)
  • No Links to Spinoff.com - Ready to Print and Share
  • Professional dossiers on over 27Tsd VC/PE/FO/ML
  • Professional dossiers on over 3Tsd MNC